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INTRODUCTION 
Disorders of carbohydrate tolerance have an immediate and significant impact 
on the outcome of pregnancy. Pregnancy in women with established 
diabetes, either insulin dependent diabetes mellitus (IDDM) or non insulin 
dependent diabetes mellitus (NIDDM), has frequently been associated with an 
adverse fetal outcome. The most frequently encountered adverse outcomes 
are related to diabetic control in the first and the third trimesters. The 
incidence of congenital malformations and early spontaneous abortions is 
associated with poor maternal diabetic control at the time of conception and 
during the first trimester. The incidence of macrosomia is largely determined 
by maternal diabetic control during the last trimester. However it was noted 
around fifty years ago that some women who had macrosomic infants 
developed diabetes shortly after delivery or during a subsequent pregnancy. 
Thus the concept of a disorder of carbohydrate metabolism or a degree of 
carbohydrate intolerance intermediate between "normality" and established 
diabetes came about. 
This intermediate state is now known as gestational diabetes mellitus (GDM) 
which is currently defined as "carbohydrate intolerance of variable severity 
with onset or first recognition during pregnancy" (Metzger, 1991). A diagnosis 
of GDM identifies a maternal/fetal unit at increased risk of certain 
complications. For the fetus there are the immediate risks associated with the 
availability of excessive nutrition during the last trimester. There is now an 
increasing body of evidence that this abnormal intrauterine nutritional milieu 
can result in problems in childhood, adolescence and in subsequent 
generations. There is also the long term risk to the mother of developing 
NIDDM in future years. 
Despite knowledge about the risks associated with a diagnosis of GDM there 
remains considerable controversy about whether the diagnosis actually exists 
and, if it does exist, how it should be diagnosed and who should be tested. 
The Australasian Diabetes in Pregnancy Society (ADIPS) and the American 
Diabetes Association (ADA) recommend that all women should be tested in all 
pregnancies. The American College of Obstetricians and Gynecologists 
(AGOG) recommend that only women with certain risk factors should be tested 
while the Royal Australian College of Obstetricians and Gynaecologists 
(RACOG) have no policy about who should be screened but a 
recommendation about the preferred method of screening! 
Hunter et al (1989) in a chapter of a widely read and influential textbook of 
obstetrics felt that, except for research purposes, all forms of glucose tolerance 
testing in pregnancy should be stopped as the potential benefits did not 
compensate for the actual disadvantages. One of the major concerns 
expressed was related to the distress of being labelled "diabetic". A less 
extreme and more reasonably argued approach against GDM as an entity 
has been advanced by Jarrett (1993) who felt that any unfavourable obstetric 
outcomes were more likely to have come about on the basis of maternal age 
and weight rather than any disorder of maternal glucose metabolism. Ales et 
al (1989) felt that the problem of macrosomia had been overated and 
problems only developed if the fetus weighed more than 4500 g. 
The proponents of GDM as a medical disorder worthy of immediate and long 
term care have several serious conceptual and methodological problems to 
overcome. There is no national or international consensus about the preferred 
method of testing for glucose intolerance, the dose of glucose to be used and 
whether the glucose tolerance test (GTT) alone is sufficiently accurate or 
reproducible to be the sole diagnostic test. One test is being used to identify 
different groups of risks in two different people. The GTT criteria currently used 
for the diagnosis of GDM have been based on either the probability of the 
mother converting to NIDDM (0"Sullivan et al, 1964) or derived by consensus 
from non-pregnant criteria (WHO, 1980). No criteria for determining the 
immediate and long term risks to the fetus have so far been validated. 
There has in recent years been an increasing body of evidence from animal 
experiments and both retrospective and prospective epidemiological data in 
humans to suggest that many "adult" diseases have some of their origins in 
disorders of fetal intrauterine nutrition. In addition, minor degrees of glucose 
intolerance below the diagnostic criteria for GDM have been found to be 
associated with many of the fetal complications found with unequivocal GDM. 
These findings have led to the suggestion that there may well exist a 
continuum of risk for the fetus associated with increasing levels of maternal 
glucose below the diagnostic level for GDM. 
The aim of this study is to examine certain aspects of fetal and maternal 
outcomes in pregnancies not complicated by GDM and to relate these to the 
maternal glucose levels. The hypothesis is that there will be a gradation of risk 
associated with increasing maternal glucose levels. 
LITERATURE REVIEW 
Literature review - Historical considerations. 
It is difficult to pinpoint exactly when it became apparent that some women 
developed a reversible form of carbohydrate intolerance during pregnancy 
and that this was associated with an increased fetal death rate and therefore 
was a substantive clinical problem. As could be reasonably expected the 
initial studies exploring the relationship between temporary maternal glucose 
intolerance in pregnancy and an increased rate of fetal morbidity and mortality 
were both retrospective and inferential. 
The concept of a particular kind of diabetes associated with pregnancy and 
antedating the onset of permanent diabetes in the mother by many years was 
first given scientific credence by Miller et al in 1944. In a retrospective study 
they found that the fetal mortality rate in pregnancies where diabetes 
developed was five times higher than in a non-diabetic control group. One-
third of the mothers who developed diabetes during the pregnancy did not 
require insulin and their fetal mortality was three times the background rate. 
This group of women could be considered to have what is now known as GDM 
though the possibility that they had NIDDM discovered during the pregnancy 
was not explored. That these women had GDM could be inferred from the 
observation that an increased perinatal mortality rate could be demonstrated 
in pregnancies 15 to 20 years before the onset of clinically recognised 
diabetes. In addition, the perinatal mortality rate increased the closer the 
women came to the eventual diagnosis of diabetes. 
Islet cell hypertrophy is a feature of stillborn fetuses of mothers with 
established diabetes. In 1952 it was demonstrated that islet cell hypertrophy 
could be found in stillborn infants of mothers without diabetes who 
subsequently developed NIDDM (Van Beek, 1952). In 1958 Jackson et al 
reported that the overall stillbirth rate in prediabetic women was 14% rising to 
29% during the 5 years before the diagnosis of diabetes. 
Also in 1958 Carrington et al presented their data of the results of testing for 
carbohydrate intolerance in pregnancy and the treatment of women with 
abnormalities - a seminal paper which could be considered the forerunner of 
modern diagnosis and treatment. Women with high risk pregnancies, with 
criteria that are now universally recognised as historical risk factors for GDM, 
had a GTT at various stages during pregnancy. Those women with abnormal 
results were treated with diet and, in a few instances, with insulin. Those 
women diagnosed and treated early had no fetal deaths while those women 
who were diagnosed at a late stage or around the time of delivery had an 
infant mortality rate of 25.6%. The observation that the "difference between 
treated and untreated patients indicate that early diagnosis is important" was 
as valid then as it is now. 
The term "gestational diabetes" appeared in the authoritative medical 
literature in 1961 (O'Sullivan). In a retrospective survey the results of glucose 
tolerance testing in 8344 high risk patients delivered between 1954 and 1959 
in Boston, USA, were presented. Using diagnostic criteria, which in some 
centres is still used today with only minor modifications, the overall incidence 
in the women tested was 0.73%. No mention was made of fetal outcome in this 
paper. Three years later the validity of the diagnostic criteria for predicting the 
conversion to NIDDM were presented (O'Sullivan et al, 1964). 
The possibility of an increased perinatal mortality rate associated with GDM 
was prospectively addressed in an observational study for the first time in 
1973 by O'Sullivan et al. A perinatal mortality rate of 6.4% in 187 pregnancies 
complicated by GDM was more than four times the rate of 1.5% in 259 control 
patients. In another observational study Pettitt et al (1980) found that the rates 
of perinatal mortality, macrosomia, toxaemia and Caesarean section varied 
directly with the maternal glucose concentration 2 hours after a 75 g glucose 
load administered in the morning without fasting. They concluded that the 
"distribution of third-trimester glucose levels were unimodal and continuous" 
and therefore it was "not possible to identify a specific level of glucose 
intolerance that can be designated as gestational diabetes". 
The selected papers outlined above, progressing from retrospective reviews to 
the delineation of gestational diabetes and to prospective observational 
studies have clearly outlined the extent and seriousness of the problem of 
GDM. It would now not be ethically possible to repeat any observational study 
unless the glucose level for non-intervention was set at such a low level as to 
make any unfavourable fetal outcome extremely improbable. While advances 
in obstetric and perinatal management continue to make pregnancy and 
childbirth an increasingly low risk event, the lessons from history can only be 
forgotten or ignored with extreme peril. 
Literature review - Diagnosis of GDM. 
There is little consensus about the ideal way of diagnosing GDM. This is due 
to methodological differences between the established criteria, difficulties in 
determining criteria sympathetic to the fetal outcomeand very real differences 
in the glycaemic responses of the populations being tested. 
The results of glucose tolerance testing in pregnancy will vary depending on 
the period of gestation (Forest et al, 1983; Hatem et al, 1988) the racial group 
(Phillipou, 1993) and perhaps the ambient temperature (Schmidt et al, 1994; 
Moses et al, 1995). When dealing with fine diagnostic margins between 
normality and GDM the GTT has been criticised for a lack of reproducibility 
(Catalano et al, 1993). 
Current clinical practices regarding testing, screening and the diagnosis of 
GDM vary considerably (Nelson - Piercy et al, 1993; Hunter et al, 1990). The 
screening tests currently employed use different glucose loads, may be used 
fasting or non - fasting, may rely on a one or two hour glucose sample and 
have variable cut off points for further testing (Cousins et al, 1991). The 
definitive oral GTT, to mention a few, may use the O'Sullivan criteria 
(O'Sullivan et al, 1964), the modification of Carpenter and Coustan (Carpenter 
et al, 1982), the National Diabetes Data Group (NDDG) criteria ( NDDG, 
1979), the WHO criteria (WHO, 1980) or in Australia the Mercy Hospital criteria 
(Abell et al, 1975) or the ADIPS criteria (Martin, 1991). 
The diagnostic criteria for GDM have concentrated on glucose measurement 
for historical reasons, ease of measurement and reproducibility between 
laboratories. It is now apparent that variations in insulin sensitivity and insulin 
resistance as well as disorders of fat and amino acid metabolism can all be an 
intrinsic part of the GDM syndrome (Ratner, 1993). Alternative diagnostic 
criteria using amniotic fluid Insulin (Persson et al, 1989) and maternal 
glycosylated proteins (Morris et al, 1986) have been suggested. Buchanan et 
al (1994) have suggested the use of fetal ultrasound measurements to Identify 
higher risk subgroups. 
Ultimately the most suitable means of defining a disease must be based upon 
the morbidity associated with that condition. The diagnosis of GDM has so far 
been almost exclusively based upon measurement of maternal glucose levels. 
For practical reasons this is likely to remain the situation for the immediate 
future. The maternal glucose level, and the method of testing, which most 
accurately defines the risks to the fetus have yet to be determined. 
Literature review - The risk to the fetus. 
It has becoming increasingly apparent that many adult diseases have their 
origins in infancy or as a result of factors operating in the intrauterine 
environment. Maternal undernutrition or specifically, protein/calorie 
malnutrition, may result in a fetus who is either small for gestational age (SGA) 
or who has a disturbance of anthropometry. Excessive fetal nutrition, perhaps 
as a consequence of maternal diabetes, may lead to a large for gestational 
age (LGA) fetus or a macrosomic fetus with excessive fat accumulation. 
Interest in the linkage between ischaemic heart disease and birth weight 
became an issue for the first time towards the end of the eighties. Barker et al 
(1989a) examined the relationship between birthweight and cardiovascular 
mortality in 5654 men born between 1911-1930 in Hertfordshire, England. 
Men with the lowest weights at birth (and at one year) had the highest death 
rates from cardiovascular disease. In England, past trends in infant mortality, 
taken as a surrogate for infant health and nutrition, correlated well with 
subsequent trends in ischaemic heart disease (Osmond, 1987). It could be 
postulated that the decline in cardiovascular deaths in other Western countries 
which began in the sixties could be related more to changes in infant morbidity 
at the turn of the century than to subsequent health interventions (Barker, 
1989b). 
The Hertfordshire report was the first part of an increasing body of 
epidemiological evidence linking low birthweights with adult onset 
hypertension (Barker et al, 1990), NIDDM (Hales et al, 1991), and high 
cholesterol concentrations (Barker et al, 1993). Thinness at birth, either 
determined by a low ponderal index or a relative reduction in abdominal 
circumference was associated with insulin resistance (Phillips et al, 1994) and 
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the features of Syndrome X (Barker et al, 1993). 
The epidemiological data outlined above also sit comfortably with the thrifty 
gene hypothesis of NIDDM (Hales et al, 1992). A significant impediment to a 
more generalised extrapolation of these findings has been the fact that the 
results have so far been confined to Caucasians living in one country. 
However corroborative data are now becoming available from different ethnic 
groups in the USA (Valdez et al, 1994). Animal experiments (Swenne et al, 
1987), at least as far as the development of diabetes is concerned, have 
suggested that protein-calorie malnutrition may be an important aetiological 
factor. 
If on one hand reduced fetal nutrition leading to low birthweights can be linked 
to serious adult diseases, then on the other hand fetal overnutrition can also 
have deleterious effects. Maternal diabetes mellitus, either established before 
the pregnancy and poorly managed during the pregnancy, or gestational 
diabetes in the last trimester are examples par excellence of this particular 
problem. In the Pima Indians the risk of subsequent diabetes was 'U' shaped 
with a higher rate for both low and high birthweight infants (McCance et al, 
1994). According to the Pedersen hypothesis (Pedersen et al, 1977), elevated 
maternal glucose levels cross the placenta and lead to an increased fetal 
insulin secretion. Fetal insulin is a potent growth factor and promotes fat 
storage of this excessive metabolic fuel resulting in a high rate of macrosomia. 
This fuel mediated teratogenesis (Freinkel, 1980) leads to an increased risk of 
several childhood, adolescent and adult onset disorders. 
Using Wistar rats it has been demonstrated that the degree of fetal islet cell 
hyperplasia at birth was correlated with the severity of the maternal diabetes 
(Aerts et al, 1977). As young adults the pups born from mothers with diabetes 
were often heavier and had impaired glucose tolerance on stimulation 
(Bihoreau et al, 1986; Gaugier et al, 1990). The mechanism of this insulin 
resistance appeared to vary depending on the severity of the maternal 
diabetes (Aerts et al, 1988). Females of the second generation had a high risk 
of developing GDM, an observation which led to the question as to whether 
GDM was an acquired condition (Aerts et al, 1979). The metabolic 
consequences of a pregnancy complicated by GDM can be detected in at 
least the third generation (Van Assche et al, 1991). 
Prospective long-term longitudinal studies of humans over several 
generations are, for obvious reasons, difficult. However the Pima Indians of 
Arizona have provided a unique opportunity for the study of GDM because of a 
very high prevalence rate of NIDDM and a tendency to develop this condition 
at an early age. The Pima Indians thus provide an excellent model for the 
study of GDM and the effect of this complication on subsequent generations. 
There is a definite genetic tendency towards NIDDM. In the Pima Indians the 
risk is significantly higher for a child to develop NIDDM if the mother rather 
than the father has had NIDDM (Knowler et al, 1985). In addition, 35% of 
patients with GDM are offspring of diabetic mothers and diabetic mothers are 
five times more likely than diabetic fathers to have a daughter who develops 
GDM (Martin et al, 1985). The data from the Pima Indians also indicate that 
there is a profound intrauterine influence in addition to any genetic tendency. 
Impaired glucose tolerance at ages 15-19 years is present in 33% of children 
whose mother had diabetes during pregnancy compared to 1.4% in children 
whose mother developed diabetes after the pregnancy (Pettitt et al, 1988). 
In the Pima Indians the probability of a child having impaired glucose 
tolerance or being a diabetic increased as the maternal glucose level 
increased following a 75g glucose challenge (Pettitt et al, 1991). This 
stratification of risk applies even for maternal results which by any criteria are 
non-diabetic. Of greatest concern, and of enormous public health importance, 
was the finding that those female offspring who had become pregnant had a 
prevalence of GDM of 18.8% if their mother's glucose during glucose 
tolerance testing in pregnancy was between 5.6-6.6 mmol/L and 50% if their 
mother's glucose level was ^7.8 mmol/L but below the level considered 
diagnostic of diabetes. 
In addition to problems associated with the development of NIDDM and GDM, 
the offspring of mothers with GDM also appear likely to have problems with 
neuropsychological development and with a lower IQ. This association was 
first made apparent by Churchill et al (1969) and later by Rizzo et al (1991). 
Thus fetal undernutrition, most likely due to maternal protein/calorie 
deprivation, and fetal overnutrition, most commonly associated with maternal 
GDM, can lead to adult diseases and problems in subsequent generations. 
There appears to be no distinct and definable point of the maternal glucose 
level at which these complications develop and a continuum of risk can be 
considered to exist (Pettitt et al, 1980). Thus criteria used to define maternal 
GDM on the basis of the subsequent risk of the mother developing NIDDM are 
most likely inappropriate for the fetal risk during and after pregnancy. With 
respect to glucose tolerance testing in pregnancy, there may be at least two 
different criteria required for two different areas of risk. 
Literature review - What are the effects of minor degrees of glucose 
intolerance on fetal and pregnancy outcomes? 
The possibility that glucose levels in the mother below the threshold for the 
diagnosis of GDM could be a risk factor for a poor pregnancy outcome was 
bought into sharp focus by Tallarigo et al (1986). This paper provided the 
stimulus for a critical examination of the previous literature and for several 
prospective studies. 
Tallarigo et al prospectively examined several pregnancy outcomes 
(macrosomia, fetal mortality, prematurity, toxaemia and Caesarean section 
rates) in 293 prenatal patients over a three year period. These women had 
had a standard 100 g GTT (O'Sullivan et al, 1964) at the beginning of the third 
trimester and did not have GDM. They were divided into three groups on the 
basis of the 2 hour plasma glucose level after the GTT. Group A had a glucose 
level ^ 5.6 mmol/L, group B had a glucose level between 5.7 and 6.7 mmol/L 
and Group C a glucose level between 6.8 and 9.1 mmol/L. 
The macrosomic rate from groups A, B and 0 were 9.9%, 15.5% and 27.5% 
respectively while the rate of maternal complications (toxaemia plus 
Caesarean section) were 19.9%, 25.9% and 40.0%. The increasing risk with 
rising maternal glucose levels could not be explained by either age or body 
weight. The women who had macrosomic infants or who had a maternal 
complication had significantly higher glucose values than those who did not. 
There are, however, some problems with this paper which could detract from 
the significance of the findings. Firstly, the type of patients who attend a 
prenatal clinic which sees less than 100 patients each year was not defined. 
Secondly, macrosomia was defined on the basis of a birthweight ^ 4,000 gms 
and was not corrected for gestational age or gender. Thirdly, the combining of 
toxaemia and Caesarean sections as an indication of maternal risk is not a 
physiological association. Fourthly the women in group C included some who 
would now be classified as having GDM by the WHO criteria. The "letter" 
criticisms which followed this publication included comments on the statistical 
methodology (Mimouni et al, 1987), the laboratory technique for measuring 
glucose (Dietrick, 1987), the inclusion of women with poor obstetric histories 
(Weiss, 1987), and the failure to adjust fetal birthweight data for the mother's 
age and weight (Jarrett, 1987). 
Despite these shortcomings and criticisms this paper did provide the 
intellectual stimulus for others to examine pregnancy outcomes in women with 
glucose levels below the diagnostic criteria for GDM. These papers can be 
loosely divided into two groups. The first group, (Li et al, 1987; Weiner, 1988; 
Roberts et al, 1993) which are generally cited as evidence that there is no 
gradation of risk with increasing maternal glucose levels, examined major 
endpoints like mortality and major degrees of morbidity. The second group, 
(Pettitt et al, 1980; Tallarigo et al, 1986; Leiken et al, 1987; Langer et al 1989; 
Lindsay et al, 1989; Kaufmann et al, 1992) which have generally found an 
increase in adverse obstetric outcomes with increasing levels of maternal 
glucose, examined softer endpoints such as the rates of macrosomia, 
induction and Caesarean section. 
In 1987 Li et al from Hong Kong compared the efficacy of the WHO GTT 
criteria to the NDDG criteria. As a side issue of this evaluation, some 
observations about perinatal outcomes were presented. On the basis of 
testing women with historical risk factors for GDM, 245/1546 (16%) had an 
abnormal NDDG GTT and 216 subsequently had a WHO GTT. Using the WHO 
criteria, 111 women (51%) had normal glucose tolerance (NGTT), 98 (45%) 
were impaired (IGTT) and 7 (3%) had diabetes. Those women who had either 
a NGTT or an IGTT were divided into a control or treatment group. The authors 
felt that the "perinatal outcome in these two groups was comparable" and 
whatever differences were apparent "probably have no clinical significance". 
This conclusion has been used by others to imply that as treatment produced 
no differences, there would appear to be little point in establishing a diagnosis 
which appeared not to be relevant. 
However there are some difficulties with these conclusions when the 
substance of the paper is studied. The patients were selected on the basis of 
historical risk factors and ultimately there were relatively low numbers 
involved. The women with IGTT who were treated had a lower mean birth 
weight, no babies weighing more than 4000 g and only 13% of babies 
weighing more than the 90 th centile compared to a rate of 24% in the 
untreated control group. No mention was made of the induction rate or the 
frequency of assisted deliveries. 
Weiner (1988) reported on the outcomes of 312 women with normal glucose 
tolerance and included a "control" group of women with GDM. The rationale 
for this was that if increasing levels of maternal glucose posed additional risks 
to the pregnancy then this should be most pronounced in women with GDM. 
Weiner found that if the glucose results of those women without GDM were 
ranked, many of the abnormalities only occurred in the highest ranked groups 
and thus did not suggest a gradient of risk. Overall there was a positive 
correlation between maternal age and the glucose result but no relationship 
between birthweight and the maternal glucose result. However there was an 
increase In the proportion of mothers who had a baby weighing more than the 
90 th centile from 4.4% if the 2 hour glucose level on the GTT was < 100 mg% 
(5.6 mmol/L) to 18.4% if the 2 hour glucose level on the GTT was between 
140-159 mg% (7.8-8.8 mmol/L). Within the same grouping the pre - eclampsia 
rate increased from 4.4% to 10.5%. This study was based upon relatively 
small numbers, relative in so far as there would need to be a much larger 
group to demonstrate the low probability of major complications like perinatal 
death or significant morbidity. The need to include a "control" group of women 
with GDM, who were all treated with either diet or a combination of diet and 
insulin, to confirm the hypothesis that the risks will continue to increase, was 
difficult to understand. 
Witter et al (1988) investigated whether the 50 g glucose challenge test was 
useful for predicting macrosomia in women without GDM. They came to the 
conclusion that minor abnormalities of carbohydrate intolerance are a risk 
factor for macrosomia but the result of the glucose challenge test was a poor 
predictor of this. The strength of this paper was the large number of patients 
examined while the weaknes was that macrosomia was the only outcome 
measured. 
The final study, which is frequently cited as showing no differences in 
pregnancy outcomes for maternal glucose levels below the threshold for GDM 
is that of Roberts et al (1993) from Belfast. Over a 47 month period 953 women 
selected according to established risk factors for GDM (and representing only 
7% of the total obstetric population) had a WHO GTT. One hundred and thirty 
five women had an impaired GTT and overall had no difference in the fetal 
outcomes selected or neonatal morbidity compared to a control group. 
However despite this reassuring conclusion, tine mothers with an impaired 
GTT had a significantly higher rate of both induced labour and Caesarean 
section. 
The papers described above were in general able to conclude that there were 
no significant differences related to varying levels of maternal glucose for the 
endpoint selected. However if less "major" endpoints had been chosen then 
each of the above papers demonstrated adverse obstetric outcomes like 
increased risks of macrosomia, induction and Caesarean section associated 
with the maternal glucose level. In this respect the above papers differ little 
from those which will be reviewed below except that those described below 
have looked at a wider and more relevant range of obstetric outcomes. 
Pettitt et al (1980) reported on the maternal and fetal outcomes of 811 
pregnancies in 604 Pima Indian women who, over a thirteen year period, all 
had had a glucose tolerance test during the third trimester. The rates of 
perinatal mortality, macrosomia, toxaemia and Caesarean section varied 
directly with the glucose concentration. In addition to maternal glucose levels, 
maternal age and weight were predictive of both macrosomia and toxaemia. 
This study has particular relevance to the patients examined in this thesis 
because, in contrast to most American studies, the dose of glucose used was 
75 g and only the 2 hour glucose level was considered. For those mothers 
with a glucose level at 2 hours of less than 5.6 mmol/L (100 mg%) a 
Caesarean section was required in 2.3%, toxaemia developed in 0.2% and 
there was a 23.2% rate of LGA infants. For those mothers with a 2 hour 
glucose level more than 11.2 mmol/L (200 mg%) the section rate was 14.3%, 
toxaemia developed in 62.5% and the rate of LGA infants was 80.0%. The 
results in between demonstrated a gradient of risk. 
There are some unusual features of the Pima Indians which make these 
absolute rates not generally applicable. They are a population who develop 
NIDDM with a very high frequency and at a relatively early age. They are also 
much heavier than the average American. However the importance of these 
figures is not the absolute rates but the definite gradation and increase of risk 
with increasing maternal glucose levels. 
Langer et al (1989) reported on the results of management in a group of 
women with one abnormal result on a glucose tolerance test. It had previously 
been demonstrated by both Langer et al (1987) and Lindsay et al (1989) that 
women with one abnormal value on a GTT done during pregnancy were more 
likely to have a fetus with macrosomia and metabolic complications than 
women with no abnormalities on their GTT. Leiken et al (1987) also reported 
similar findings and furthermore felt that the risk associated with the maternal 
glucose level remained after adjustment for other macrosomic risk factors. 
Kaufmann et al (1992) were unable to demonstrate that women with one 
abnormal value had a higher rate of LGA after correction of birth weight for 
gestational age. The suggestion was made that higher glucose levels may 
result in slightly longer gestational period. The observation was also made 
that the current NDDG criteria for GDM may be too high for predicting those 
women who would have a LGA infant. 
The purpose of the 1989 study of Langer et al was to see if intervention in the 
group with one abnormal value could reduce neonatal morbidity. All women 
had a 50 g glucose challenge test followed in those who were positive by a 
100 g glucose load GTT. Glucose values were interpreted according to the 
NDDG criteria. There were 126 women with one abnormal value on their GTT 
(2 abnormal values being required for the diagnosis of GDM) and they were 
randomly divided into two groups. One group continued with their usual diet 
while the other group received treatment with diet and/or insulin as if they had 
GDM. There were 146 women in a control group who had had a normal GTT. 
Of the women with one abnormal value on their GTT, the treated group has a 
significant reduction in neonatal metabolic complications and in the number of 
large infants compared to the untreated group. There were no significant 
differences in pregnancy outcomes between the treated group and the control 
group. 
What these studies have demonstrated is that women who do not meet the 
criteria for GDM but who have one abnormal value on the GTT are at 
increased risk of adverse pregnancy outcomes. The adverse outcomes 
considered have been the rate of macrosomia, toxaemia and the need for 
Caesarean section. The study of Langer et al (1989) demonstrated that 
intervention in these women can produce results similar to those women 
without any abnormality on glucose tolerance testing. 
The studies of Pettitt et al (1980) and Tallarigo et al (1986) differ from those 
mentioned above. The observations about potential adverse pregnancy 
outcomes were extended to all levels of glucose and suggested a gradation of 
risk. The difficulties with these two studies are that Tallarigo et al were dealing 
with a relatively small number of patients and, from the information available, 
an unusual prenatal clinic arrangement. The study of Pettitt et al was based on 
the Pima Indians and information from this group has to extrapolated with 
care. 
The present study herein reported overcomes some of the methodological 
problems in the papers discussed above. The number of patients included is 
by far the largest of any series so far reported. The maternal and fetal 
outcomes have been assessed across the whole range of maternal glucose 
values. A comparison group of women with treated GDM have also included. 
All of the papers reviewed above have used diagnostic criteria for GDM that 
use higher glucose levels than the ADIPS criteria used for the patients in this 
study. Consequently many of the patients with one abnormal value on a GTT 
would certainly have been classified as GDM by the ADIPS criteria. Thus the 
patients used in this study with a 2 hour glucose level < 8.0 mmol/L would be 
considered unequivocally normal by any other criteria and thus should help to 
settle the question as to whether there is a gradation of obstetric risk 
associated with increasing levels of maternal glucose. 
PATIENTS AND METHODS 
This study was carried out in tine lllawarra area of New Soutli Wales. Data 
were collected from the prenatal clinics at Wollongong and Shellharbour 
hospitals and from cooperating obstetricians. 
Methods: Diagnosis. 
The diagnosis of GDM was based on the recommendations of the 
Australasian Diabetes in Pregnancy Society (ADIPS) (Martin, 1991). ADIPS 
specified that a definitive diagnosis of GDM was to be made after the 
administration of a WHO standard GTT at the beginning of the third trimester. 
The WHO GTT requires the administration of 75 g of anhydrous glucose in 
300 mis of water in the morning after an overnight fast with venous samples 
taken fasting and at two hours. GDM is diagnosed if the fasting plasma 
glucose is ^ 5.5mmol/L and/or the two hour plasma glucose level is ^ 8.0 
mmol/L. 
Some patients in this study had a GTT and some had a modification of the 
GTT (MGTT). With the MGTT the standard WHO GTT was used but only the 
two hour sample was collected (Moses, 1992). The ADIPS criteria of a two 
hour plasma glucose ^ 8.0 mmol/L was used for diagnosis. 
Glucose samples were processed in air conditioned premises either by the 
biochemistry department of Wollongong hospital or by two private pathology 
companies. Laboratory standards were comparable as each performed 
satisfactorily on national Quality Assurance programs for all routinely 
measured analytes including glucose. The venous sample for plasma glucose 
was collected fasting and/or at two hours, immediately separated after 
collection and stored at 40C until analysed. Analysis was done by Wollongong 
hospital using a glucose oxidase method on a Kodak Ecktachem 700XRC 
(Rochester, USA). Analysis was done by the pathologists in private practice 
using a hexokinase method on an Olympus REPLY (Tokyo, Japan). 
Methods: Data collection procedures 
For the first six months of 1993 the prenatal clinic at Wollongong Hospital 
offered the MGTT to all women while the prenatal clinic at Shellharbour 
Hospital offered all patients a GTT. From July 1993, and for the remainder of 
the period of data collection, this situation was reversed. Only those prenatal 
clinic patients who were screened during 1993, and who had delivered by the 
end of April 1994, have been included. 
Additional data were obtained from two specialist obstetricians and a general 
practitioner with an interest in obstetrics who offered a MGTT to all of their 
patients from the beginning of 1993. A third obstetrician agreed to collect data 
from the beginning of 1994. The patient data from these sources were all 
women who were tested until the end of February 1994. 
Data collection at the Wollongong Hospital was done by a midwife working in 
the prenatal clinic. After a short evaluation period, a system of data collection 
suitable for the procedures and staff at Wollongong Hospital was introduced. 
Data collection at Shellharbour Hospital was done by a midwife working in the 
Labour Ward who examined the prenatal clinic records several times each 
week. It was not possible at Shellharbour Hospital for information about 
previous GDM or whether there was a positive family history of diabetes in a 
first degree relation to be obtained. Both midwives were on a monthly retainer. 
Data collection by the private obstetricians was collated by their staff using a 
standardised system. Data about previous GDM and a family history of 
diabetes was not practicable to collect. The general practitioner collected all 
data herself. 
Methods: Pregnancy and fetal outcome data. 
Pregnancy and fetal outcome details were obtained from the NSW Midwives' 
Data Collection Form. It is a requirement of the NSW Department of Health 
that this form be completed by staff at the hospital from which the mother was 
eventually discharged after the completion of the pregnancy. In the lllawarra 
area this was Wollongong Hospital, Sheilharbour Hospital or The lllawarra 
Hospital. The lllawarra Hospital is a private hospital where some private 
patients were transferred to after delivery. Parts of the Midwives' form were 
completed by the Labour Ward staff after delivery and the balance by the staff 
of the obstetric wards. 
It was not logistically possible to obtain the required data from the the 
Midwives' forms at the time of discharge from hospital. The Midwives' forms 
were obtained from the respective Medical Records Departments at a later 
date during the process of coding. The Medical Record Departments did not 
have the resources available to search for and present all of the Midwives' 
forms to match all of the patients who had had glucose tolerance testing. 
During the coding process the Midwives' forms were set aside, collected by 
myself on a regular basis and copied for future data entry. Dependent on the 
generosity of the Medical Records Departments, it was not practicable to ask 
for details of those patients whose forms did not become available by these 
means. However there was no reason to believe that the forms of any patients 
were held back or were dealt with in any manner which would not have made 
them available. 
All data were stored on a Macintosh LC using Statview (Abacus Concepts, 
Berkeley, California). 
Methods: Data collection - tvoe and definitions. 
The maternal data collected included name, the month and year at which the 
glucose tolerance testing was done, the hospital or obstetrician responsible 
for the care, the age of the patient when tested, parity, preconception weight 
by recall, height, the ethnic background of the mother, the number of weeks 
gestation at which the glucose tolerance testing was done, whether the 
procedure was a GTT or a MGTT and the glucose result fasting and at 2 
hours. Body Mass Index (BMI) was calculated by dividing the preconception 
weight in Kg by the height in metres squared. 
The information required for this survey from the Midwives' form included the 
following; whether there was Pregnancy Induced Hypertension and 
gestational diabetes; whether labour was spontaneous or induced; the 
method of delivery; whether the fetus was alive or dead; fetal gender; plurality; 
birthweight in grams; gestational age at delivery; Apgar score at 10 minutes; 
neonatal morbidity. The Apgar score is an index used to evaluate the 
condition of the newborn infant with a rating of 0 - 2 for each of the following 
five characteristics; colour, heart rate, response to stimulation of the sole of the 
foot, muscle tone and respiration. 
Ethnic background. The mother's country of birth was recorded and grouped 
into geographical areas; Australasia (Australia, excluding aboriginals, and 
New Zealand), northern Europe, southern Europe, Asian, Indian, Aboriginal, 
Pacific Islanders and others. Because of small numbers the ethnic groups of 
Asian, Indian, Aboriginal, Pacific Islanders and "others" have been 
presented in the Results section as "others". Women were classified as 
Southern European if they came from a country with a border on the 
Mediterranean Sea. 
Pregnancy induced Hypertension fPIHV The presence or absence of this 
complication was obtained from the Midwiyes' Data Form. 
Induction. This information was obtained from the Midwiyes' Data Form. 
Labour was either spontaneous or induced. The different types of induction 
were not distinguished. Those women who had an electiye Caesarean 
section were excluded from this section. 
Method of deliyery. This information was obtained from the Midwiyes' Data 
Form. The different methods of deliyery were; spontaneous yaginal, forceps 
assisted, yacuum extraction, electiye Caesarean section and emergency 
Caesarean section. 
Neonatal morbidity. This information was obtained from the Midwiyes' Data 
Form. "Morbidity" was defined as the need for a baby to be admitted to a 
special care nursery. This facility was only ayailable at Wollongong hospital 
and thus deliyeries at Shellharbour hospital were excluded. 
Methods: Exclusions. 
The primary exclusions from this survey were those patients whose Midwives' 
Data Form was not available using the means of collection mentioned above. 
Data on patients were included if they had been tested after 24 weeks of 
gestation, delivered after 32 weeks of gestation and had had a singleton live 
fetus. 
With diverse people responsible for completing the Midwives' forms there 
were inevitably some clerical omissions. Fetal birthweight was available on an 
estimated 99% of all forms. After the exclusions mentioned above, only those 
patients who had the fetal birthweight recorded were used for the survey. 
Inevitably a small amount of some of the other data were incomplete. 
Methods: Statistical methods. 
Unless specified otherwise, results have been expressed as a percentage or 
as a mean with one standard deviation in parentheses. The statistical 
methods used included the two-sample pooled t - test, Chi-squared analysis, 
multiple regression analysis and logistic regression analysis. Unless 
otherwise stated the result of the 2 hour glucose level after the GTT (gtt2) in 
the contingency tables have been presented in the following groups; ^ . 9 , 
4.0 - 4.9, 5.0 - 5.9, 6.0 - 6.9, 7.0 - 7.9 and, for women with GDM, as ^ 8.0 
mmol/L respectively. The fasting glucose level (gttO) was available in 389 
instances. Unless otherwise stated the gttO data were arranged in the 
contingency tables in the following groups; ^3.9, 4.0-4.1, 4.2-4.3, 4.4-4.5 
and ^4.6 mmol/L respectively. 
In order to determine at what level of gtt2 the risk of non-GDM mothers 
experiencing a particular characteristic (eg, non-vaginal delivery) would be 
equivalent to the risk experienced by the treated GDM mothers, the following 
calculation was used. Each risk was transformed by converting it to equivalent 
odds. When the risk for a particular event for GDM mothers was within the 
range of risks for non-GDM mothers, the odds of having this condition could 
be modelled by logistic regression in which the gtt2 was used as the predictor. 
As will be shown in the Results section, this situation only applied to large for 
gestational age infants (LGA) and pregnancy induced hypertension (PIH). 
For example, for GDM mothers the odds of having PIH is 16/108. The log of 
these odds is - 1.9095. The equation which predicts the odds of PIH in terms 
of gtt2 for non-GDM mothers is log (odds) = -3.5253 + 0.2065 x gtt2. If - 1.9095 
is set equal to - 3.5253 + 0.2065 x gtt2, then the value of gtt2 can be found 
which makes these equal. 
All analyses were conducted on the University of Wollongong's SUN 4/470 
mainframe computer, using the statistical package SAS Institute, Inc, Box 
8000, Gary, NC, USA 27511-8000. Some analyses were checked using the 
statistical package Genstat, which is produced by the Numerical Algorithms 
Group Ltd, Mayfield House, 256 Banbury Road, Oxford, United Kingdom 0X2 
7DE. 
Methods: Ethical approval. 
Ethical approval for this research was provided by the Human Research 
Ethics Committee of the lllawarra Area Health Service and the University of 
Wollongong. 
RESULTS 
Data were available on 1441 normal pregnancies and 125 pregnancies in 
women with GDM who had had a singleton live fetus. The gender of the fetus 
was recorded in all but two instances and males comprised 51.0% of the total. 
A GTT was done in 388/1441 (26.9%) cases and a MGTT in 1053/1441 
(73.1%) cases. 
Maternal demographic, obstetric and birthing details for all of the normal 
women by different ethnic groups are shown in table 1. 
Table 1. 
Maternal demographic, obstetric and birthing details according to the ethnic 
origin - mean (1SD). 
Australasian N. European 8. European Others 
n=1062 n=126 n=115 n=115 
Age in years 27.2 (5.0) 28.1 (4.7)* 26.9 (4.7) 27.6 (5.6) 
Parity 0.9 (1.0) 0.9 (1.0) 1.0 (1.2) 0.9 (1.2) 
BIVII (Kg/m2) 23.9 (4.6) 23.9 (4.6) 24.7 (4.7) 22.8 (4.6) * 
Week of test 28.0 (1.9) 28.4 (2.0) * 27.50(1.9) ** 28.2 (2.1) 
gtt2 (mmol/L) 5.6 (1.0) 5.7 (1.0) 5.7 (1.0) 5.8 (1.1)* 
Birthweight (g) 3448 (519) 3420 (519) 3412 (451) 3394 (482) 
Gest. age (weeks) 39.5 (1.4) 39.5 (1.4) 39.6 (1.3) 39.3 (1.4) 
*p<0.05, ** p<0.01. 
The women of Northern European origin were significantly older and the 
women in the "others" group (mainly Asian) had a significantly lower 
preconception BMI. The number of women from different ethnic groups were 
relatively small compared to the Australasian group and therefore only the 
total number has been subsequently used for data analysis. 
Maternal demographic, obstetric and birthing details for the normal women 
according to the maternal gtt2 level are shown in table 2. 
Table 2. 
Maternal demographic, obstetric and birthing details for normal women 
according to the maternal gtt2 level - mean (1SD). 
Maternal glucose Age Parity 
(mmol/L) (years) 
^ 3.9 mmol/L 28.2 (3.8) 1.0 (0.9) 
n = 83 
4.0 - 4.9 mmol/L 27.1(5.0) 0.9(1.0) 
n = 291 
5.0-5.9 mmol/L 27.0 (4.9) 0.9 (1.0) 
n = 561 
6.0-6.9 mmol/L 27.4(5.1) 0.9(1.0) 
n = 363 
7.0-7.9 mmolL 28.3 (5.3) 0.7 (1.0) 
n = 142 
BMI Birth weight Gest. age 
(Kg/m2) (grams) (weeks) 
22.3 (3.2) 3308 (487) 39.2 (1.6) 
23.2 (4.0) 3403 (504) 39.5 (1.5) 
23.7 (4.6) 3452 (480) 39.6 (1.3) 
24.7 (5.0) 3462 (522) 39.6 (1.4) 
24.5 (4.9) 3471 (624) 39.5(1.5) 
Maternal demographic, obstetric and birthing details for the total of all normal 
(non-GDM) women and the GDM mothers are shown In table 3. 
Table 3. 
Maternal demographic, obstetric and birthing details for the total of non-GDM 
mothers and for GDM mothers - mean (1SD). 
Total non-GDM GDM 
n = 1441. n = 125. 
Age In years 27.3 (5.0) 29.1 (5.2) 
Parity 0.9 (1.0) 0.8 (1.0) 
BMI (Kg/m2) 23.8 (4.6) 26.0 (5.7) 
Week of test 28.0 (2.0) 28.1 (1-9) 
gtt2 (mmol/L) 5.6 (1.1) 8.9 (1.6) 
Birthweight (g) 3438 (512) 3402 (477) 
Gest. age (weeks) 39.5 (1.4) 39.3 (1.4) 
* p < 0.0001 
The women with GDM were significantly older, had a higher preconception 
BMI and a higher (by definition) gtt2 level. There were no differences with 
respect to parity, birthweight and the gestational age of delivery. 
Results: Frequency of assisted delivery. 
Deliyeries were classified as normal yaginal or assisted (forceps, yacuum 
extraction, elective Caesarean section or emergency Caesarean section). 
Table 4. 
Percentage of normal vaginal and assisted deliveries according to the 
maternal gtt2 level. 
Maternal glucose normal vaginal % assisted % total 
^3.9mmol/L 86.1 13.9 (n = 79) 
4.0-4.9 mmol/L 76.7 23.3 (n = 283) 
5.0-5.9 mmol/L 77.7 22.3 (n = 548) 
6.0-6.9 mmol/L 72.5 27.5 (n=353) 
7.0-7.9 mmolL 69.6 30.4 (n = 138) 
^8 .0 mmol/L 66.9 33.1 (n = 121) 
A Chi-squared analysis of contingency tables (for non-GDM mothers only) was 
used to examine whether the proportions of normal vaginal and assisted 
deliveries for non-GDM mothers were the same for each category of gtt2. 
There was a significant association between the level of gtt2 and the 
proportion of deliveries which were assisted (X2=10.799, df. = 4. p = 0.029). 
The tendency was for the proportion of assisted deliveries to increase as the 
gtt2 increased. 
The mean gtt2 levels were examined using a two-sample pooled t - test to see 
whether a significant difference existed between those mothers who had or 
had not had an assisted delivery. An assisted delivery was performed in 
358/1421 (25.2%) of mothers who had a mean gtt2 level of 5.8 (1.0) mmol/L. 
This was significantly higher than the mean gtt2 level of 5.5 (1.0) mmol/L for 
the 1063/1421 (74.8%) mothers who did not have an assisted delivery (t = 
4.941. df. = 1419, p = 0.0001). 
The logistic regression predicted equation for the odds that a birth would be 
an unassisted vaginal were logit(p) = -3.4481 - 0.0434 x BMI - 0.0694 x age + 
0.5302 X parity + 0.2047 x gestational age - 0.1646 x gtt2. 
Each of the variables BMI (p < 0.01), mothers age (p < 0.01), parity (p < 0.01), 
gestational age of delivery (p < 0.01) and gtt2 (p < 0.02) were statistically 
significant in the presence of the others. 
The odds in favour of a normal vaginal delivery are estimated to increase by 
69.9% for each increase of one in the parity and by 22.7% for each advancing 
week of gestational age. The odds in favour of a normal vaginal delivery are 
estimated to decrease by 4.3% for each one unit increase in BMI, by 6.7% for 
each year increase in mothers age, and by 15.2% for each 1.0 mmol/L 
increase in gtt2. 
The risk that a delivery for a GDM mother was assisted was outside the risks 
for non-GDM mothers. Hence it was not feasible to estimate the value of gtt2 
which made the risk for non-GDM mothers equal to the risk for a GDM mother. 
The various types of assisted deliveries were examined separately and are 
presented in table 5. It was necessary to pool the two gtt2 categories of ^ 3.9 
and 4.0-4.9 to provide sufficient numbers for analysis. 
The Chi-squared test was used for non-GDM mothers only to test the null 
hypothesis that the relative proportions of the various types of deliveries were 
the same across the various levels of gtt2. The Chi-squared test suggested 
that the relative proportions were not constant (X2 = 22.658, df. = 12, p = 
0.0308). This came about because the number of forceps assisted deliveries 
and emergency Caesarean sections were larger than expected in the 
category 7.0-7.9 mmol/L and the number of emergency Caesarean sections 
were less than expected for gtt2 levels in the category 5.0-5.9 mmol/L. 
Table 5. 
Percentage of normal vaginal and different assisted deliveries according to 
the maternal gtt2 level. 
Maternal glucose Vaginal Forceps Vacuum Elective Emerg. 
Caesar Caesar 
^4.9 mmol/L 78.7 1.4 5.3 7.5 7.2 
n = 362 
5.0-5.9 mmol/L 77.7 2.2 7.3 6.9 5.8 
n = 548 
6.0-6.9 mmol/L 72.5 2.0 6.8 9.6 9.1 
n = 353 
7.0-7.9 mmolL 69.6 5.8 4.4 8.0 12.3 
n = 138 
^8.0 mmol/L 67.7 3.9 9.5 11.0 7.9 
n = 121 
The mean gtt2 levels were examined using a two-sample pooled t - test to see 
whether a significant difference existed between those mothers who had, or 
had not, undergone Caesarean section (elective and emergency). A 
Caesarean section was performed in 217/1441 (15.1%) of mothers who had a 
mean gtt2 level of 5.8 (1.0) mmol/L. This was significantly higher than the 
mean gtt2 level of 5.6 (1.0) mmol/L for the 1224/1441 (84.9%) mothers who 
did not have a Caesarean section (t = 3.0078, df. = 1439, p = 0.0027). 
There were 377 women who had a gttO level < 5.5 mmol/L. There was no 
significant association between the gttO level and whether the delivery was 
vaginal or assisted (X2 = 7.480, df. = 4, p = 0.113). There was also no 
significant association between the gttO level and the method of assisted 
delivery (X2 = 9.122, df. = 8, p = 0.332). 
Results: Parity 
With respect to Caesarean sections, a previous section for any reason is likely 
to result in a subsequent section. The following contingency table outlines the 
rates of elective and emergency section with parity. 
Table 6. 
Percentage of selected deliveries and maternal parity. 
parity = 0 parity ^ 1 total 
non-Caesar 40.0 % 60.0 % (n = 1183) 
Elect. Caesar 22.7% 77.3% (n = 110) 
Emer. Caesar 69.2 % 30.8 % (n = 107) 
This table demonstrates a significant association (X2 = 50.805, df. = 2, p < 
0.001) between parity and the type of section. Of those women who had a 
Caesarean section, women in their first pregnancy were far more likely to have 
an emergency section while women in their second and subsequent 
pregnancy were more likely to have an elective section. 
There were 118 normal women who had a Caesarean section and who had 
had two or more pregnancies. Data about previous deliveries were available 
in 116 women of whom 79 (68.1%) had had a previous section while 37 
(31.9%) had not. There were 13 women with GDM who had a Caesarean 
section and who had had two or more pregnancies. Of these 13 women 7 
(53.8%) had had a previous section while 6 (46.2%) had not. 
Results: Pregnancy induced hypertension (PIH). 
The percentage of women with PIH according to their gtt2 leyel are shown in 
table?. 
Table 7. 
Percentage of women with PIH according to the maternal gtt2 leyel. 
Maternal glucose no PIH PIH total 
^ 3.9 mmol/L 92.8 7.2 n = 83 
4.0-4.9 mmol/L 91.7 8.3 n = 290 
5.0-5.9 mmol/L 93.4 6.6 n = 562 
6.0-6.9 mmol/L 89.3 10.7 n = 363 
7.0-7.9 mmolL 86.6 13.4 n = 142 
^8.0mmol/L 87.1 12.9 n = 121 
The proportion of mothers suffering from PIH increased as the gtt2 leyel 
increased though with the Chi-squared analysis for the non-GDM mothers this 
trend did not quite reach significance (X2 = 9.304, df. = 4, p = 0.054). Howeyer 
the mean gtt2 leyels of the 125/1440 (8.7%) mothers who did haye PIH at 5.8 
(1.1) mmol/L was significantly higher than the mean gtt2 leyels of the 
1315/1440 (91.3%) mothers who did not haye PIH at 5.6 (1.0) mmol/L (t = 
2.2497, df. = 1438. p = 0.0246). 
There was no significant association between the gttO leyel and the rate of 
PIH (X2 = 1.540, df. = 4. p = 0.820). 
The logistic regression predicted equation for the odds of pregnancy induced 
hypertension were logit(p) = 6.1764 + 0.1074 x BMI - 0.5654 x parity - 0.2940 
X gestational age + 0.1343 x gtt2. 
Each of the variables BMI (p < 0.01), parity (p < 0.01) and gestational age of 
delivery (p < 0.01) were statistically significant in the presence of the others. 
The variable gtt2 was not statistically significant. 
The odds in favour of PIH are estimated to increase by 11.9% for each 
increase of one unit in BMI. The odds in favour of PIH are estimated to 
decrease by 25.3% for each one week increase in gestational age and by 
44.1% for each increase of one in parity. 
Non-GDM women with a gtt2 of ^ 7.8 mmol/L had a risk for PIH which 
exceeded the risk for treated GDM women. 
Results: Rate of induction. 
Labour was eitlier classified as spontaneous or induced. Those women who' 
had an elective Caesarean section have been excluded. 
Table 8. 
Percentage of women who were induced according to their maternal gtt2 
level. 
Maternal glucose no induction % induced % total 
^3.9mmol/L 76.3 23.7 (n = 80) 
4.0-4.9 mmol/L 70.6 29.4 (n = 265) 
5.0-5.9 mmol/L 81.2 18.8 (n = 522) 
6.0-6.9 mmol/L 76.2 23.8 (n=327) 
7.0-7.9 mmolL 75.4 24.6 (n = 130) 
^8.0 mmol/L 62.7 37.3 (n = 110) 
A Chi-squared analysis of the contingency table for non-GDM mothers 
revealed a significant association of the gtt2 level with the rate of induction (X2 
= 11.796, df = 4, p = 0.019). However as can be seen from the table, the 
percentage of induced births for mothers does not trend upwards with the level 
of gtt2. The rate of induction for mothers with gtt2 levels ^ 3.9 or ^ 6.0 mmol/L 
are fairly constant and between 23 and 24%.For those mothers whose gtt2 
level is 4.0-4.9 mmol/L the percentage of births induced is 29.4% while for 
those mothers with a gtt2 level of 5.0-5.9 mmol/L the rate falls to 18.8%. There 
was no significant association between the gttO level and whether the labour 
was induced (X2 = 6.184, df. = 4, p = 0.186). 
The logistic regression predictive equation for the odds that a birth would be 
induced are logit(p) = -12.7454 + 0.0533 x BMI + 0.0312 x age - 0.1922 x 
parity + 0.2574 x gestational age - 0.1328 x gtt2. 
Each of the variables BMI (p < 0.01), mothers age (p < 0.02), parity (p < 0.02), 
gestational age of delivery (p < 0.01) and gtt2 (p < 0.05) were statistically 
significant in the presence of the others. 
The odds in favour of an induced birth are estimated to increase by 6.2% for 
each increase of one in the BMI, by 3.7% for each increase of one year in the 
mother's age and by 23.0% for each week in gestational age. The odds in 
favour of an induced birth are estimated to decrease by 16.9% for each one 
unit increase in parity and by 12.7% for each 1.0 mmol/L increase in gtt2. 
Results: Birthweiaht of the babv. 
The birthweights were considered in both absolute and relative terms. 
Birthweiaht in absolute terms. 
In absolute terms a birthweight of ^ 2,500 g was called small for gestational 
age (SGA) while a birthweight of ^ 4,000 g was called large for gestational 
age (LGA) irrespective of the gender or the gestational age of delivery. 
Table 9. 
Percentage of absolute SGA and LGA according to the maternal gtt2 level. 
Maternal glucose SGA % LGA % total 
^ 3.9 mmol/L 6.0 6.0 (n = 83) 
4.0-4.9 mmol/L 4.5 12.4 (n = 291) 
5.0-5.9 mmol/L 2.1 12.8 (n = 562) 
6.0-6.9 mmol/L 3.6 13.5 (n = 363) 
7.0-7.9 mmolL 4.9 15.5 (n = 142) 
^8.0mmol/L 0.8 10.5 (n = 124) 
The Chi-squared test of the contingency table did not suggest for non-GDM 
mothers a significant association between gtt2 level and the percentage of 
babies who were either SGA or LGA (X2 = 8.302, df. = 4, p = 0.0811). There 
was also no significant association for non-GDM mothers between the gttO 
level and the percentage of babies who were either SGA or LGA (X2 = 
14.706, df. = 4, p = 0.065). There were no significant differences in the LGA 
rate for treated women with GDM (13/124, 10.5%) and the non-GDM women 
(184/1441, 12.8%) and for the SGA rate for treated women with GDM (1/124, 
0.8%) and the non-GDM women (50/1441, 3.5%). 
A baby weighing ^4500 g was found in 29/1441 (2.0%) of the non-GDM 
pregnancies. The rates did not differ significantly for the maternal gtt2 groups 
which were 2/83 (2.4%) for gtt2 ^ 3.9 mmol/l, 4/291 (1.4%) for gtt2 4.0-4.9 
mmol/L, 11/562 (2.0%) for gtt2 5.0-5.9 mmol/L, 7/363 (1.9%) for gtt2 6.0-6.9 
mmol/L and 5/142 (3.5%) for gtt2 7.0-7.9 mmol/L. Three of the one hundred 
and twenty four (2.1%) women with treated GDM had an infant weighing ^ 
4500g. 
The mean gtt2 level of the 184 mothers who had a LGA baby was 5.8 (1.0) 
mmol/L which was significantly higher than the mean gtt2 level of 5.6 (1.0) 
mmol/L for the 1207 women who had a baby > 2,500 g and < 4,000 g (t = 
2.436, df 1390, p < 0.02). The mean gtt2 level of the 50 mothers who had a 
SGA baby was 5.6 (1.2) mmol/L which was not significantly different to the 
women with a baby > 2500 g and < 4000g. 
In absolute terms the odds that a baby would be large for its gestational age 
were modelled in terms of the BMI, age of the mother, gtt2 and the gestational 
age of delivery. The influence of maternal age and gtt2 were found not to be 
significant (p >0.1). When just BMI and gestational age were fitted, both were 
significant (p < 0.001). The odds in favour of a LGA baby are estimated to 
increase by 7.5% for an increase of one unit of BMI and by 61.2% for each 
week of gestational age. 
The odds that a baby would be small for its gestational age were modelled in 
terms of the BMI, age of the mother, gtt2 and the gestational age of delivery. 
The influence of BMI, mothers age and gtt2 were not found to be significant (p 
>0.1). The variable gestational age explained the odds to a significant extent 
(p < 0.001). The odds in favour of a SGA baby are expected to decrease by 
63.7% for each increase of one week in gestational age. 
The estimated value of gtt2 for which the risk of a non-GDM mother having a 
LGA baby in absolute terms was equal to the risk of a treated GDM mother 
was 4.4 mmol/L. 
Birthweiqht in relative terms. 
Sufficient data was available for deliveries between 37 and 42 weeks 
inclusive to calculate birthweight centiles based upon gender and the 
gestational age of delivery. In relative terms SGA and LGA were based on the 
tenth and ninetieth centiles respectively. 
Table 10. 
Percentage of relative SGA and LGA according to the maternal gtt2 level. 
Maternal glucose <10 th centile % > 90 th centile % total 
^3.9mmol/L 13.3 6.7 (n = 75) 
4.0-4.9 mmol/L 13.3 8.1 (n = 271) 
5.0-5.9 mmol/L 9.0 11.6 (n = 533) 
6.0-6.9 mmol/L 10.9 10.6 (n = 341) 
7.0-7.9 mmolL 8.4 13.7 (n = 131) 
^8.0 mmol/L 5.9 11.0 (n = 118) 
The Chi-squared test of the contingency table did not suggest for non-GDM 
mothers a significant association between gtt2 level and the percentage of 
babies who were either SGA or LGA in relative terms (X2 = 8.528, df. = 4, p = 
0.0740). There was no significant association between the gttO level for non-
GDM mothers and the percentage of babies who were either SGA or LGA in 
relative terms (X2 = 10.219, df. = 8, p = 0.250). There were no significant 
differences in the LGA rate for treated women with GDM (13/118, 11.0%) and 
the non-GDM women (143/1441, 9.9%) and for the SGA rate for treated 
women with GDM (7/118, 5.9%) and the non-GDM women (144/1441, 10.0%). 
The mean gtt2 level of the 143 mothers who had a LGA baby was 5.8 (1.0) 
mmol/L which was significantly higher than the mean gtt2 level of 5.6 (1.0) 
mmol/L for the 1066 women who had a baby neither SGA nor LGA (t = 2.415, 
df 1253, p < 0.02). The mean gtt2 level of the 142 mothers who had a baby 
SGA was 5.5 (1.1) mmol/L which was not significantly different to the women 
with a baby neither SGA nor LGA. 
In relative terms the odds that a baby would be LGA were modelled in terms of 
the BMI, age of the mother and the gtt2 result. The influence of the gtt2 level 
was not significant (p >0.1). When just BMI and mothers age were fitted both 
were significant (p < 0.001 for BMI and p < 0.002 for mother's age). The odds 
in favour of a LGA baby are estimated to increase by 9.6% for each increase of 
one unit in BMI and by 6.0% for each year in mother's age. 
The odds that a baby would be small for its gestational age were modelled in 
terms of the BMI, mothers age and the gtt2 level. The influence of age and the 
gtt2 level were not significant (p >0.1). When just BMI was fitted, it was 
significant (p < 0.001). The odds in favour of a SGA baby are expected to 
decrease by 8.3% for each increase of one unit in BMI. 
The estimated value of gtt2 for which the risk of a non-GDM mother having a 
LGA baby in relative terms was equal to the risk of a treated GDM mother was 
5.9 mmol/L. 
Results: Aoaar score. 
The following contingency table shows the level of gtt2 in the mother and the 
Apgar score for the baby. In order to obtain sufficient babies in each column of 
the table, those babies with scores between 0 and 6 were grouped into one 
category. 
Table 11. 
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A Chi-squared analysis of the contingency table for mothers without GDM 
suggested that there was no association between gtt2 and the Apgar score 
(X2 = 8.792, df. = 16, p = 0.922). There was also no significant association with 
gttO (X2 = 18.025. df. = 16, p = 0.322). 
Results: Mnrhiriity 
The following table displays the percentage of babies with "morbidity" 
according to the gtt2 level. Deliveries at Shellharbour hospital have not been 
included as there was no special care nursery available. 
Table 12. 
Percentage of babies who were admitted to the special care nursery and thus 
deemed to have "morbidity" according to the maternal gtt2 level. 
Maternal glucose no "morbidity" "morbidity" total 
^ 3.9 mmol/L 76.0 24.0 (n = 75) 
4.0-4.9 mmol/L 71.6 28.4 (n = 257) 
5.0-5.9 mmol/L 71.3 28.7 (n = 506) 
6.0-6.9 mmol/L 67.0 33.0 (n = 330) 
7.0-7.9 mmolL 63.2 36.8 (n = 133) 
^ 8.0 mmol/L 32.2 67.8 (n = 115) 
The Chi-squared analysis of the contingency table for non-GDM mothers did 
not suggest any significant association of the level of gtt2 and "morbidity" (X2 = 
6.356, df. = 4, p = 0.174). There was also no significant association with the 
gttO level (X2 = 4.997, df. = 4, p = 0.288) 
The 394 (30.3%) mothers who had a baby with "morbidity" had a mean gtt2 
level of 5.8 (1.1) mmol/L which was significantly higher than the mean gtt2 
level of 5.5 (1.0) mmol/L for the 907 (69.7%) mothers whose baby did not have 
this complication (t = 3.54, df. = 1299, p < 0.001). 
As it was conventional practice to admit to the SCN tine babies of mothers who 
had had an assisted delivery, the results of those mothers who were "Yes" for 
morbidity were further analysed. With respect to unassisted deliveries, 
morbidity was present in 8/65 (12.3%) of mothers with a gtt2 level ^ 3.9, in 
26/210 (12.4%) of mothers with a gtt2 level 4.0 - 4.9, in 65/426 (15.3%) of 
mothers with a gtt2 level 5.0 - 5.9, in 38/259 (14.7%) of mothers with a gtt2 
level of 6.0 - 6.9 and in 21/104 (20.2%) of mothers with a gtt2 level of 7.0 - 7.9 
mmol/L respectively. With respect to unassisted deliveries, the mean gtt2 level 
of 5.7 (1.1) mmol/L of the 161 mothers who were "Yes" for morbidity was 
significantly higher than the 5.5 (1.0) mmol/L of the 791 mothers who were 
"No" for morbidity (p < 0.02). 
The logistic regression predicted equation for the odds of morbidity were 
logit(p) = 8.4821 + 0.0340 x BMI - 0.2867 x gestational age + 0.2036 x gtt2. 
Each of the variables BMI (p < 0.02), gestational age of delivery (p < 0.01) and 
gtt2 (p < 0.01) were statistically significant in the presence of the others. 
The odds in favour of being rated "Yes" for morbidity are estimated to increase 
by 3.5% for each one unit increase in BMI and by 22.6% for each unit in gtt2. 
The odds in favour of being rated "Yes" for morbidity are estimated to 
decrease by 24.9% for each one week increase In gestational age. 
DISCUSSION. 
Data were available on 1.441 normal pregnancies representing about half of 
all the deliveries in the lllawarra area during the time of the survey. There is no 
reason to suppose that the women included in this study were in any way 
different to the overall local obstetric population. When grouped according to 
their gtt2 result the women who had a glucose ^ 3.9 mmol/L and between 7.0 
and 7.9 mmol/L were significantly older than the other women. There was no 
apparent reason for this and adjustments for this were made in the logistic 
regression analysis. The mean BMI rose progressively from 22.3 in women 
with a gtt2 result ^ 3.9 mmol/L to 24.5 in women with a gtt2 result of 7.0 - 7.9 
mmol/L and there was also a progressive increase in mean birthweight from 
3308 gm to 3471 gm. The women with a gtt2 result of ^ 3.9 mmol/L had a 
slightly lower gestational age of delivery compared to the other groups which 
were otherwise very similar to each other. 
There were 125 women diagnosed with GDM of whom 110 were cared for by 
one person (RM) and treated in a standard way (Moses, 1994b). The overall 
incidence of GDM was 8.0% which was similar to an earlier report from the 
lllawarra area (Moses et al, 1994a) which used some of the patients included 
in this series. As could be anticipated the women with GDM were older and 
had a higher preconception BMI than the non-GDM mothers. There were no 
differences between the GDM women and the normal women with respect to 
parity, the number of weeks gestation at which the glucose testing was done, 
the mean birthweight of the babies and the gestational age of delivery. These 
results reinforce previous observations that parity per se is not a risk factor for 
GDM and well controlled women with GDM can proceed to full term. 
There is considerable variation in the rate of GDM in women from different 
countries (Hadden, 1985) and in women from different ethnic backgrounds in 
Australia (Beischer et al, 1991; Moses et al, 1994a). In Australia, Asian women 
have a one of the highest rates of GDM but generally have a lower than 
average BMI. The normal women in this study did show some differences in 
maternal demography when grouped according to ethnic origin. Women from 
Northern Europe were slightly older while the "others" group, comprised 
mainly of women from Asia, had a lower BMI and a higher gtt2 result. 
Unfortunately, even in this large study, there were insufficient women in the 
different ethnic groups to determine if any significant differences existed in the 
maternal and fetal outcomes studied. The differences in maternal demography 
outlined above could be considered of minor clinical significance, and, as 
nearly three-quarters of all the women were of Australasian origin, the results 
of all the women were grouped and considered as a whole. 
With respect to the diagnosis of GDM, and therefore the classification of 
women without GDM, the ADIPS recommendation specified either a 
preliminary glucose challenge test in the non-fasting state followed by a 
definitive two hour GTT in the fasting state or a two hour GTT in the fasting 
state used alone. 
There are potential and real problems associated with a two stage diagnostic 
procedure. A hypertonic glucose solution is unpleasant to take for most 
people at any time and is particularly so in pregnancy. The experience of the 
first test must inevitably dissuade some from taking the second test with a 
consequent reduction in the diagnostic usefulness. No published reports have 
so far considered the problem of the "no show". Other researchers in this field, 
albeit from developing countries, (C Deerochanawong and P Porcera: 
personal communication) have indicated that as many as 40% of patients do 
not present for the second glucose test. A two stage diagnostic procedure 
must also result in a delay in diagnosis and therefore treatment which, as 
pregnancy is a limited event, may have an impact on outcome. 
It would therefore appear logical to "screen" and diagnose at the same time 
using the GTT. The problem with the GTT is that it is an inconvenient 
procedure requiring two venepunctures and at least a two hour presence in a 
laboratory collection area. In the lllawarra area, and there is no reason to 
suspect that this area is any different from other areas in Australia, there was 
some reluctance by obstetricians to test for GDM because of perceptions 
about the inconvenience of the procedure to their patients. These concerns 
were addressed in two ways. Firstly, a survey was conducted of patients with 
GDM (Griffiths et al, 1993) which showed that, after an explanation was 
provided about the Importance of screening, pregnant women were not only 
willing to have this procedure but expected this to be conducted as an 
important part of routine antenatal care. Secondly, a modification of the GTT 
(MGTT) was introduced. 
The MGTT, which was used for diagnosis in 73.1% of cases was found to be 
a convenient testing procedure for the following reasons (Moses, 1992). The 
glucose solution, instructions and explanations were provided in the prenatal 
clinic or the obstetrician's office making a visit to the laboratory and the need 
to make an appointment for the GTT unnecessary. The glucose solution was 
drunk at home and the patient presented two hours later for a plasma glucose 
test. This test could also be combined with other routine antenatal 
investigations. This method of testing was found to be very convenient by the 
obstetricians in private practice. 
The major criticism of tiiis one test screening/diagnostic procedure was tliat by 
not taking tlie fasting sample those women who had an elevated fasting 
glucose but a normal two hour glucose would be missed. The logic is 
undeniable that the MGTT will therefore underdiagnose the rate of GDM. The 
percentage of patients who will be missed is not known for certain but is likely 
to be small. It was considered that increased compliance with a simplified 
testing procedure would compensate for the possible small number of patients 
who might be missed by not doing the fasting sample. 
The clinical significance of a woman with a raised fasting glucose level and a 
normal two glucose level is doubtful. Concerns about relying on a fasting 
sample have recently been raised by the WHO (WHO, 1994) and the fasting 
sample has for many years been dispensed with entirely by Pettitt et al (1994) 
in their ongoing observational studies of the Pima Indians. For these very 
practical reasons I have suggested that it is now time to modify the GTT for the 
diagnosis of gestational diabetes (Moses, 1995a). 
There have been several recent reports suggesting that the two hour glucose 
sample may be elevated at times of high ambient temperatures leading to the 
over diagnosis of GDM in summer and a lower rate of diagnosis in winter 
(Akanji et al, 1987; Akanji et al, 1991; Schmidt et al, 1994). This possibility of 
temperature induced changes in the gtt2 level were specifically examined in 
the patients used in this series and no clinically significant effect was found 
(Moses et al, 1995b). 
Selected aspects of the maternal and fetal outcomes were examined. A higher 
rate of most adverse outcomes have generally been found in women with 
GDM and it was the purpose of this study to see whether a continuum of risk 
existed across the glucose range of normal women. 
The result of the fasting glucose level (gttO) was available in nearly 400 
normal women. Unlike the gtt2 level to be discussed below, the gttO level did 
not appear to be associated with any of the pregnancy outcomes considered. 
Specifically, the gttO level was not associated with whether the delivery was 
normal vaginal or assisted, the type of assisted delivery, the rate of PIH, the 
rate of induction, the Apgar score or morbidity. The gttO level was also not 
associated with the percentage of babies who were LGA or SGA in either 
relative or absolute terms. 
Assisted deliveries are an established part of modern obstetric practice. 
Women with GDM have in the past had a higher rate of assisted delivery, 
mainly Caesarean section, due to macrosomia and associated problems. 
Recently the tight metabolic control of GDM has resulted in very favourable 
fetal outcomes with respect to macrosomia and a reduction in the Caesarean 
section rate, in some series, to that not significantly different from women 
without GDM (Langer et al, 1994; Drexel et al, 1988; Thompson et al, 1994.) 
Where the Caesarean section rate for women with GDM is similar to the rate in 
normal women, the usual indication for a Caesarean section is a previous 
history of a Caesarean section (Jacobson et al, 1989). In the series herein 
reported two - thirds of the normal muciparous women having a Caesarean 
section had had a previous Caesarean section. For the multiparous women 
with GDM who had a Caesarean section more than half had had a previous 
Caesarean section. Where the Caesarean section rate remains higher despite 
good control of GDM, it is often based on the preference of the obstetrician 
and not always on defined obstetric indications (Kitzmiller et al, 1992). 
For the normal women the decision about the method of delivery was made by 
the obstetrician responsible and there Is no reason to presume that the 
possible knowledge of the normal glucose result would have in any way 
influenced this decision. The frequency of assisted deliveries increased in 
virtually all categories of gtt2 from 13.9% in those women with a gtt2 ^ 3.9 
mmol./L to 30.4% in those women with a gtt2 level of 7.0-7.9 mmol/L The 
exception to this tend were the women with a gtt2 result of 5.0 - 5.9 mmol/L 
who also had the lowest mean age. Women with a gtt2 result of 7.0 - 7.9 
mmol/L had the highest rate of both forceps delivery and of emergency 
Caesarean section. Overall those women who had an assisted delivery or a 
Caesarean section had a significantly higher mean glucose level than the 
other women. The odds in favour of a normal vaginal delivery increased very 
significantly with increasing parity and increasing gestational age. These 
findings were not unexpected as a previously successful vaginal delivery is 
likely to result in further successful vaginal deliveries and many interventional 
decisions are likely to take place before full term. 
In a controlled evaluation Peipert et al (1993) confirmed previous anecdotal 
obstetric literature that there was an increased rate of Caesarean section with 
advancing age. While different variables were examined as possible 
explanations, the carbohydrate status of the women was not tested. In the 
normal women herein reported the odds in favour of an assisted delivery 
increased a small amount for each increase in BMI and maternal age. 
However the odds in favour increased by 15.2% for each increase of 1.0 
mmol/L in gtt2. Thus it would seem possible that the previously observed 
increase in obstetric interventions with increasing maternal age could be 
related to an increasing, but still "normal", maternal glucose level. 
There are a large number of different reasons as to why a decision could be 
made to recommend either an elective or an emergency Caesarean section, 
in addition to conventional obstetric indications there are also social and 
demographic indications like the socio-economic status of the mother (Gould 
et al, 1989), obstetrician preferences (Goyer et al, 1989) and increasing 
maternal age (Peipert et al, 1993). Vaginal delivery compared to a Caesarean 
section, even after a previous Caesarean section (Miller et al, 1994), has a 
lower complication and death rate (Petti et al. 1982, Miller et al, 1988) avoids 
the psychological impact of a surgical delivery (Eriksen et al, 1989) and is less 
expensive particularly with a decreased length of hospital stay (Clark et al, 
1991). 
As dietary intervention in women with GDM can reduce the number of large 
babies and hence one of the major indications for a Caesarean section, it is 
tempting to postulate that dietary intervention in women without GDM but with 
a high normal glucose level may also reduce the Caesarean section rate. 
These results demonstrate in normal women that, after correcting for other 
variables, there is an increasing probability of an assisted delivery, principally 
an emergency Caesarean section, as the gtt2 level increases. This was a 
particular problem for women with a gtt2 result of 7.0 - 7.9 mmol/L. 
Pregnancy induced hypertension (PIH) is a poorly understood and probably 
heterogeneous group of disorders which affects 6.2% of all pregnancies in 
NSW (NSW Midwives Data Collection 1993). Hypertension of all kinds 
(Jacobson et al, 1989) and specifically PIH is found with increased frequency 
in women with GDM (Norlander et al, 1989; Langer et al, 1989; Drexel et al, 
1988). An increased rate of PIH is also found in women without GDM who 
have one abnormal value on their GTT (Lindsay et al, 1989). A Finnish 
prospective study of the relationship between gestational glucose intolerance 
and PIH is relevant to the present study (Suhonen et al, 1993). In this study 
GDM was defined using lower glucose criteria than the ADIPS criteria and 
therefore included many women who would have been in the non-GDM 7.0-
7.9 mmol/L group herein reported. PIH was present in 19.8% of women with 
GDM which was significantly higher than the rate of around 7.0% found in 
controls. 
The percentage of women with PIH in the current study increased from 7.2% 
in those women with a gtt2 level ^ 3.9 mmol/L to 13.4% in those women with a 
gtt2 level of 7.0 - 7.9 mmol/L. Those women with PIH had a significantly higher 
gtt2 level than those women without this complication. The treated women 
with GDM had a rate which was similar to the women with a gtt2 level of 7.0 -
7.9 mmol/L and certainly did not show the increasing trend which could have 
been anticipated. 
For normal women the increasing trend of PIH with rising levels of gtt2 was not 
significant when the effect of the rising BMI was considered. The odds in 
favour of PIH increased by 11.9% for each one unit increase in BMI. A very 
substantial reduction in the odds was found for both gestational age and 
parity. The reduction in odds for these factors could have been anticipated as 
a women with PIH would be likely to have been induced early and, in addition, 
may not be encouraged or inclined to have further pregnancies. 
Thus while the risk of PIH increased as the gtt2 level increased the most likely 
explanation for this was the increasing BMI rather than the glucose level per 
se. However either an increasing gtt2 level or an increasing BMI could be 
predictive of an increased risk of PIH. 
A decision to induce labour can be made on a large number of factors. 
Surprisingly, although the Chi-squared analysis of the contingency tables did 
suggest a significant association with the rate of induction and the gtt2 level, 
this did not increase as the gtt2 level increased. Rather the association was 
caused by a lower than expected frequency in the women with a gtt2 level 
between 5.0-5.9 mmol/L who were younger than the other groups. The overall 
rate of induction for women in the lowest glucose group were similar the 
overall rate for women in the highest glucose group. 
Thompson et al (1994) reported that women with GDM had an overall 
induction rate of 32%. Women with treated GDM in this series had the highest 
overall rate of induction, a rate that was nearly twice that of the rate in non-
GDM women in the 5.0 - 5.9 mmol/L gtt2 group. Again, like the increased rate 
of assisted deliveries, this high rate is probably both traditional and 
precautionary and is likely to gradually change with time. 
The odds in favour of an induced birth increased by 6.2% for each one unit 
increase in BMI and decreased by 12.7% for every 1.0 mmol/L increase in the 
gtt2 level. 
Large for gestational age (LGA) babies have in the past been a common 
feature of women with GDM. Possible obstetric complications include birth 
trauma, shoulder dystocia, asphyxia, meconium aspiration and neonatal 
hypoglycaemia. A full term infant weighing more than 4500 g has a risk of 
mortality three to four times that of infants with an average birth weight 
(Spellacy et al, 1985). An increased rate of testing for GDM and an aggressive 
modern approach to management have reduced the rate of this complication 
to a level similar to that of the overall obstetric population (Norlander et al, 
1989; Suhonen et al, 1993; Moses, 1994b). Macrosomia as a complication of 
GDM is now most commonly found in women who have not been tested for 
this problem or who are unreliable with the treatment advice (Moses, 1994b). 
The rate of macrosomia is still frequently used as the single most important 
indicator of the successful medical management of a woman with GDM 
though it is increasingly recognised that the birthweight is more likely to be 
determined by maternal variables than glycaemic control (Shelley-Jones et al, 
1992; Cundy et al, 1993). The concern about macrosomia, while of arguable 
value for the obstetric management, is assuming greater importance as the 
effects of varying degrees of nutrition on the intrauterine development of fetal 
organs is becoming increasingly recognised and acknowledged as an 
associate and possible cause of many problems in adult life. Maternal 
hyperglycaemia of any cause results in fetal hyperinsulinism and 
overdevelopment of the fetal pancreatic islets. 
Macrosomia can be defined in various ways including an arbitrary absolute 
figure such as a birthweight of ^ 4000 g or relatively by using the tenth centile 
of birthweight adjusted for gender and gestational age. The rate of 
macrosomia in Canada has remained unchanged over the sixties and the 
seventies (Boyd et al, 1983) while in Australia between the seventies and 
eighties there has been a gradual increase corresponding to an increase in 
the frequency of GDM (Shelley-Jones et al, 1992). While macrosomia is a 
relatively common complication of diabetes and pregnancy it is still most 
likely to be related to obvious factors like the gestational age of delivery, the 
size of both parents, maternal age, parity, fetal gender and less obvious 
factors like socioeconomic status (Ratten et al, 1974) and even geographical 
features like altitude (Sack 1969). 
In the series herein reported the rate of absolute macrosomia increased from 
6.0% in normal women with a gtt2 result ^ 3.9 mmoi/L to 15.5% in the normal 
women with a gtt2 result of 7.0 - 7.9 mmol/L. Overall those normal women who 
had a macrosomic infant had a gtt2 result which was significantly higher than 
those who did not. However when other variables were examined the 
maternal gtt2 level no longer remained as a significant factor. There was an 
anticipated increase in the rate of macrosomia with increasing gestational age 
and also with increasing maternal preconception BMI. With respect to 
absolute macrosomia the increased rate in women with increasing levels of 
gtt2 could be explained by an increasing level of BMI. 
In the series herein reported the rate of relative macrosomia increased from 
6.7% in normal women with a gtt2 result ^ 3.9 mmol/L to 13.7% in normal 
women with a gtt2 result of 7.0 - 7.9 mmol/L. Overall those women who had a 
macrosomic infant had a gtt2 level which was significantly higher than those 
who did not. However when other variables were examined the maternal gtt2 
level no longer remained as a significant factor. There was an increase in the 
rate of macrosomia with increasing maternal age and also with increasing 
BMI. With respect to relative macrosomia the increased rate in women with 
increasing levels of gtt2 could be explained mainly by an increasing level of 
BMI. 
Small for gestational age (SGA) infants also are an undesirable outcome of 
any pregnancy and recent epidemiological data suggests a link between 
reduced fetal growth and the adult development of hypertension (Barker et al, 
1990) and NIDDM (Barker et al. 1993b). Reduced fetal growth can be due to 
a variety of causes (King et al, 1994) and even possible over treatment of 
GDM (Langer et al, 1989). Langer et al (1989) felt that the fetus would grow 
within limits set by the nutrient supply and fetal insulin levels are susceptible 
to substrate availability in either direction. The rate of SGA was significantly 
related in treated women with GDM to the low mean daily maternal glucose 
levels. In contrast, Dornhorst et al (1991) in a small series found no treated 
woman with GDM had an infant with a birth weight less than the 10 th centile 
and in the series herein reported there was no significant difference in the rate 
of SGA for treated women with GDM compared to normal women when both 
relative and absolute birth weights were considered. 
In the series herein reported the rate of SGA in absolute terms was dependent 
on the gestational age of delivery and not to the maternal gtt2 level or the 
BMI. The rate of SGA in relative terms was not related to the maternal gtt2 
level but decreased as the BMI increased. There is thus nothing to suggest in 
normal women that maternal glucose levels per se will influence the rate of 
SGA. 
There have been a limited number of reports linking maternal glucose levels 
with the rate of macrosomia. Leiken et al (1987) felt that minor degrees of 
glucose intolerance were likely to result in an increased rate of macrosomia. 
However the maternal glucose level was not specified and testing had been 
done only on women with historical risk factors for GDM. In addition, although 
different variables were considered as the possible cause of this association, 
the maternal BMI was not examined. The following year Witter et al (1988) 
also concluded that minor degrees of carbohydrate intolerance were 
associated with an increased risk of macrosomia though they felt that the 50 g 
glucose 1-hour screening test was a poor discriminator. 
In 1994 Khan et al published a report on a large number of Pakistani women 
relating maternal glucose results to the rate of macrosomia. This study has 
many similarities and also some notable differences to the present series. All 
pregnant women attending the Aga Khan University Medical Center in 
Karachi had a 75 g non-fasting glucose challenge test (GCT) at 16-20 weeks 
gestation with a single venous glucose sample taken at 2 hours. If the result 
was > 7.8 mmol/L a GTT was carried out. Those women with a normal GCT 
and those women with an abnormal GCT and a normal GTT were stratified 
into different groups depending upon their 2 hour glucose response to the 
GCT. 
The rate of macrosomia, defined as a birthweight > 4000 g, increased from 
1.2% in women with a glucose < 4.5 mmol/L to 9.5% in women with a glucose 
> 7.8 mmol/L. Similar significant trends were found when the 90 th and 95 th 
birthweight centiles were used. Macrosomia was not related to the gestational 
age of delivery, probably because pre and post term deliveries had been 
excluded. 
There are both close similarities and some differences between the study of 
Khan et al and the present study. The population studied were Pakistani 
women who undoubtedly would have had a lower birthweight than the 
predominantly Anglo-Saxon population group herein reported. Testing was 
done at an earlier stage of pregnancy which would have reduced the number 
of abnormal results to the GCT and thus would have led some women to be 
included in the non-GDM group who would probably have been classified 
differently if the test had been done 8-10 weeks later. The GCT was also 
done in a non-fasting state though there is now evidence to suggest that this is 
unlikely to make any major difference to the result (Gough et al. 1970). The 
use of a 75 g glucose load and the 2 hour glucose sample were the same as 
the present study. The use of a glucose result ^ 7.9 mmol/L to define 
abnormality Is similar to the value of ^ 8.0 mmol/L recommended by ADIPS 
and used In this study. No adjustment was made for the fetal gender In 
determining the birthwelght centlles. Whereas Khan et al have found an 
Increase in the rate of macrosomla with increasing maternal glucose levels, 
no adjustment was made for maternal BMI. In the present study the maternal 
BMI rather than the gtt2 level was the Important factor. 
Jarrett (1993) in a deliberately provocative review argued that GDM was a 
non-diagnosis and that any association between fetal birthwelght and 
maternal glucose is lost when adjustments are made for maternal weight and 
age. Leiken et al (1987) and Boyd et al (1983) found that lean women have a 
lower rate of macrosomla. Green et al (1991) found that maternal body habitus 
was the strongest predictor of fetal birthwelght. In the study by Green et al 
there was no significant relationship between the maternal glucose level on a 
screening test and fetal birthwelght after adjustment for the gestational age of 
delivery, fetal gender, parity, ethnicity and BMI. However after adjustment for 
the above variables there was a progressive increase In fetal birthwelght for 
increasing levels of BMI. There are two possible difficulties with these 
observations. BMI was determined at the time of the screening test at the 
beginning of the third trimester and both overweight women and women with 
GDM gain relatively less weight during pregnancy (Snyder et al, 1994; Cundy 
et al, 1993). Cundy et al found that the fetal birthwelght In women with 
established diabetes and GDM was correlated with the preconception BMI 
and not with glycaemic control or with the glucose level in control (non 
diabetic) pregnancies. Women who were diagnosed as having GDM appear 
to have been included in the overall figures with no mention of any treatment. 
Not withstanding these confounding variables, the present study also agrees 
with the above reports that fetal birthweight and the rate of macrosomia are 
related to maternal glucose levels only because maternal glucose levels in 
normal women are largely determined by the maternal BMI. The odds in 
favour of a baby weighing ^ 4000 g increased by 7.5% for each one unit 
increase in BMI and the odds in favour of a baby being above the 90 th centile 
for gestational age and gender increase by 9.6% for each one unit increase in 
BMI. 
Morbidity for the purposes of this survey was defined according to the 
question on the Midwives form - "Did the baby require admission to a separate 
facility/nursery for special care or observation". Morbidity, in this series, is thus 
dependent upon the availability of a designated special care area. Within the 
lllawarra area a special care nursery (SCN) was only available at the 
Wollongong hospital and deliveries at Shellharbour hospital were therefore 
not included in the analysis. The decision to admit a baby to the SCN was 
made by the obstetrician/ paediatrician responsible for the delivery and was 
made independently of any possible knowledge the normal maternal glucose 
level. 
The normal women who had their baby admitted to the SCN had a higher 
mean gtt2 than the normal women who did not and the odds in favour of an 
admission increased by 22.6% for each 1.0 mmol/L increase in the gtt2 result. 
With respect to some obstetric and fetal outcomes the positive association with 
the gtt2 level was largely explained by a higher maternal BMI. This does not 
appear to be the case with respect to morbidity as the odds in favour of being 
rated "Yes" for morbidity only increased by 3.5% for each one unit increase in 
BMI. 
It was not possible in this survey to determine the reason for admission to the 
SCN as this was, in a majority of instances, not recorded in the medical 
record. Decisions were no doubt precautionary as well as based upon 
established medical indications. It is conventional practice to admit the babies 
of all women who have had an assisted delivery to the SCN and about half of 
the admissions were for this reason. However, after exclusion of those women 
who had an assisted delivery the mean gtt2 level of those women whose 
babies were admitted to SCN was still significantly higher than the gtt2 level of 
those women whose babies were not admitted to the SCN. These results 
indicate that whatever fetal indications were present leading to a decision to 
admit to the SCN, these were more often found in women with a higher gtt2 
level. 
CONCLUSIONS 
GDM is a potentially serious disorder requiring vigilance and effective medical 
managennent. While most modern series of obstetric care have found no 
significant differences in perinatal mortality between treated women with GDM 
and the general obstetric population, this is partly due to a continuing 
improvement in obstetric care and partly because it is most unlikely that there 
are any diagnosed women with GDM who do not receive some form of 
treatment. Historical lessons can only be ignored with peril. Perinatal mortality 
is a finite end point but a very crude index of maternal and fetal care for 
developed countries in the nineties. In a sophisticated medical environment, 
and one that is becoming increasingly litigious, maternal and fetal outcomes 
will be judged on more subtle criteria. The induction rate, the frequency of 
assisted deliveries and the use of special care nurseries are all relevant to 
"best practice" obstetrics and to administrators concerned with the costs of 
health care. The intrauterine effects on the fetus of disorders or deviations of 
maternal nutrition are likely to have profound effects on the later development 
of adult diseases. 
There can be no doubt that there are adverse fetal risks associated with 
maternal glucose levels sufficiently high for a diagnosis of GDM to be 
established. It is logical to presume that there will exist a continuum of risk for 
maternal glucose levels of a lesser degree. The relationship of these risks to 
the maternal glucose levels are more likely to be exponential rather than 
linear. The statistical threshold for maternal glucose levels at which these risks 
will become apparent will certainly vary depending on the risk being defined 
and with the population examined. Where the risk will be defined will depend 
upon the resources available for both detection and treatment. 
An appropriate definition of GDIVI should be based on maternal and fetal 
outcomes, both during the pregnancy and in later years. The risks to the fetus 
seem to be present at a lower maternal glucose level than the glucose level 
that will predict the future conversion of the mother to NIDDM. For the normal 
women in this study the frequency of assisted deliveries and the probability of 
being admitted to a special care nursery were all increased, after adjustment 
for other variables, as the maternal glucose level increased. The rate of 
macrosomia was also related to rising maternal glucose levels but could be 
explained by a rising BMI. However in the clinical context, defining a 
pregnancy at risk of having a macrosomic fetus on the basis of maternal 
glucose levels and using maternal glucose levels to monitor the effects of 
interventions are more likely to produce favourable outcomes than any 
consideration of the BMI. 
The gtt2 level in normal women is predictive of certain adverse pregnancy 
outcomes. Dietary treatment in women with GDM can reduce the rate of 
adverse outcomes associated with this condition. It is possible that dietary 
interventions in normal women who have a gtt2 level in the higher range may 
lead to an increased proportion of women with a normal pregnancy and a 
reduction in health care costs. 
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APPENDIX 
Birthweiqht of males bv gestational aae. 
Weeks gestation mean (SD) lOthcentile 90th centile 
37. n = 32 
38. n = 89 
39. n = 119 
40. n = 307 
41. n = 120 



















Birthweiqht of females bv gestational aae. 
Weeks gestation mean (SD) lOthcentile 90th centile 
37. n = 20 
38. n = 90 
39. n = 122 
40. n = 303 
41.n = 106 



















Birthweiqht (total) bv gestational age. 
Weeks gestation mean (SD) lOthcentile 90th centile 
37. n = 52 
38. n = 179 
39. n = 241 
40. n = 610 
41. n = 226 
42. n = 43 
3016 (495) 
3187 (441) 
3387 (421) 
3545 (473) 
3667 (411) 
3584(407) 
2322 
2700 
2806 
2930 
3161 
3018 
3805 
3686 
3910 
4130 
4206 
4084 
